Back to top
more

Masimo (MASI)

(Real Time Quote from BATS)

$136.74 USD

136.74
96,841

+0.60 (0.44%)

Updated Apr 29, 2024 11:38 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (94 out of 252)

Industry: Medical - Instruments

Better trading starts here.

Zacks News

Masimo (MASI) Just Overtook the 200-Day Moving Average

Should investors be excited or worried when a stock crosses above the 200-day simple moving average?

What's in Store for Edwards Lifesciences (EW) in Q4 Earnings?

Edwards Lifesciences' (EW) Q4 results are likely to reflect continued demand for its state-of-the-art HemoSphere monitoring platform and Smart Recovery portfolio in Critical Care.

Masimo (MASI) Gains on Favorable Ruling in Apple Watch Dispute

Masimo (MASI) rides on the continuation of the import ban on certain models of Apple watches using disputed blood oxygen sensors.

Here's How Much a $1000 Investment in Masimo Made 10 Years Ago Would Be Worth Today

Investing in certain stocks can pay off in the long run, especially if you hold on for a decade or more.

Quest Diagnostics (DGX) to Post Q4 Earnings: What's in Store?

Quest Diagnostics' (DGX) fourth-quarter 2023 results are likely to reflect the robust strength of its base business.

What's in Store for Boston Scientific (BSX) in Q4 Earnings?

Boston Scientific (BSX) is expected to have witnessed strong growth of the WATCHMAN franchise in the fourth quarter, given the FDA approval of WATCHMAN FLX Pro in September.

Align Technology (ALGN) to Post Q4 Earnings: What's in Store?

Align Technology's (ALGN) fourth-quarter 2023 results are likely to reflect the strength of the Clear Aligner and Systems & Services businesses.

Here's Why You Should Retain Masimo (MASI) Stock for Now

Masimo's (MASI) R&D activities raise optimism about the stock.

Masimo (MASI) Posts Preliminary Q4 Results, Issues FY24 View

Masimo's (MASI) fourth-quarter 2023 results are likely to reflect the impacts of the robust adoption of hearable products.

Apple (AAPL) Halts Smartwatch Sales Ban Amid Patent Dispute

Apple (AAPL) wins a temporary reprieve in the patent battle over its smartwatches, pausing an import ban amid a legal clash with Masimo over medical tech.

Zacks Investment Ideas feature highlights: Nike, Apple, Masimo and Micron Technology

Nike, Apple, Masimo and Micron Technology are part of the Zacks Investment Ideas article.

Bryan Hayes headshot

Famed Santa Claus Rally Begins: Stocks to Watch

Today marks the final trading day before Christmas and is also the first day of a period known as the Santa Claus Rally.

Masimo's (MASI) Stork Baby Monitoring System Approved by FDA

The latest FDA clearance of Masimo's (MASI) Stork smart home baby monitoring system is likely to provide a continuous and accurate view of babies' health data.

Masimo's (MASI) ORi Favored by Study for PaO2 Information

Masimo's (MASI) latest study indicates that ORi can be a valuable tool to provide information on arterial oxygenation even during OLV.

Masimo's (MASI) W1 Medical Watch to Boost Patient Monitoring

Masimo's (MASI) receipt of the latest FDA approval is expected to provide greater visibility of changes in oxygen saturation to help patients better manage their oxygen levels daily.

Masimo's (MASI) Latest Tie-Up to Boost Patient Monitoring

Masimo's (MASI) latest joint effort is likely to enable real-time continuous monitoring with a tailored view of the patient's vitals while keeping them mobile during critical recovery periods.

Company News for Nov 9, 2023

Companies in The News Are: RL,OXY,AKAM,MASI

Masimo (MASI) Q3 Earnings Beat Estimates, Margins Fall

Masimo's (MASI) overall third-quarter results reflect soft performance despite strength in the Hearables category.

Compared to Estimates, Masimo (MASI) Q3 Earnings: A Look at Key Metrics

Although the revenue and EPS for Masimo (MASI) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Avinger (AVGR) Reports Q3 Loss, Lags Revenue Estimates

Avinger (AVGR) delivered earnings and revenue surprises of -2.46% and 24.29%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Philips (PHG) Aids Clinicians With New Monitoring Solution

Philips (PHG) launches Visual Patient Avatar to help anesthesiologists with situational awareness in operating rooms, boosting their clinical confidence.

Masimo (MASI) Gets De Novo for Novel Oxygen Status Index ORi

Masimo's (MASI) ORi parameter gets De Novo from the FDA, providing option for continuous monitoring of oxygen level in surgical patients leading to better management of hyperoxia.

Masimo's (MASI) LiDCO to Boost Hemodynamic Monitoring Post CE Mark

Masimo's (MASI) LiDCO is likely to offer clinicians a BIC solution designed to provide a more complete picture of oxygen delivery.

Philips (PHG) Expands Mobile C-arm Portfolio With Zenition 30

Philips (PHG) expands its mobile C-arm lineup with Zenition 30, which provides surgeons with more control and customization.

Masimo's (MASI) Inks Agreement to Improve Patient Outcomes

Masimo's (MASI) latest deal with FMOLHS is expected to enhance patient safety and improve patient outcomes.